|
|
 | | | |
- close
- close
- close
- close
This excerpt taken from the SHPGY 8-K filed Feb 20, 2007. 2. Product sales For the year to December 31, 2006 product sales increased by 16% to $1,535.8 million (2005: $1,327.7 million) and represented 86% of total revenues (2005: 83%). This excerpt taken from the SHPGY 10-Q filed Nov 7, 2006. Product sales The following table provides an analysis of the Company’s key product sales:
40 * REPLAGAL was acquired in the acquisition of TKT which was completed on July 27, 2005. Total sales for REPLAGAL, including pre-acquisition sales for the 3 months ended September 30, 2005 were $24.1 million. Including pre-acquisition sales, product sales growth was 34% for REPLAGAL. The following discussion includes references to prescription and market share data for the Company’s key products. The source of this data is IMS Health, September 2006. IMS Health is a leading global provider of business intelligence for the pharmaceutical and healthcare industries. This excerpt taken from the SHPGY 8-K filed Oct 27, 2006. 2. Product sales For the three months to September 30, 2006 product sales increased by 25% to $386.2 million (2005: $309.2 million) and represented 86% of total revenues (2005: 82%). This excerpt taken from the SHPGY 10-Q filed Aug 4, 2006. Product sales The following table provides an analysis of the Company’s key product sales:
* REPLAGAL was acquired in the acquisition of TKT which was completed on July 27, 2005. 43 The following discussion includes references to prescription and market share data for the Company’s key products. The source of this data is IMS Health, June 2006. IMS Health is a leading global provider of business intelligence for the pharmaceutical and healthcare industries. This excerpt taken from the SHPGY 8-K filed Jul 28, 2006. 2. Product sales For the three months to June 30, 2006 product sales increased by 7% to $376.0 million (2005: $351.6 million) and represented 85% of total revenues (2005: 83%). This excerpt taken from the SHPGY 8-K filed Apr 27, 2006. 2. Product sales For the three months to March 31, 2006 product sales increased by 28% to $346.0 million (2005: $269.4 million) and represented 84% of total revenues (2005: 81%). This excerpt taken from the SHPGY 10-K filed Mar 1, 2006. (i) Product sales Revenue for the sales of products is recognized upon shipment to customers or at the time of delivery depending on the terms of sale. Provisions for rebates, product returns and discounts to customers are provided for as reductions to revenue in the same period as the related sales are recorded. The Company monitors and tracks the amount of sales deductions based on historical experience to estimate the amount of reduction to revenue. This excerpt taken from the SHPGY 8-K filed Feb 23, 2006. 2. Product sales For the year to December 31, 2005 product sales increased by 19% to $1,327.7 million (2004: $1,112.5 million) and represented 83% of total revenues (2004: 82%). Excluding post acquisition sales of REPLAGAL ($41.3 million), product sales for 2005 increased by 16%.
This excerpt taken from the SHPGY 10-Q filed Nov 9, 2005. Product sales For the nine months to September 30, 2005, product sales increased 16% to $930.1 million (2004: $803.6 million) and represented 82% of total revenues (2004: 81%). The following table provides an analysis of the Company’s key product sales:
50 The following discussion includes references to prescription and market share data for the Company’s key products. The source of this data is IMS Health, September 2005. IMS Health is a leading global provider of business intelligence for the pharmaceutical and healthcare industries. This excerpt taken from the SHPGY 8-K filed Nov 3, 2005. 2. Product sales For the three months to September 30, 2005 product sales increased 9% to $309.2 million (2004: $283.7 million) and represented 82% of total revenues (2004: 82%). This excerpt taken from the SHPGY 8-K filed Jul 28, 2005. 2. Product sales For the three months to June 30, 2005, product sales increased 38% to $351.6 million (2004: $255.3 million) and represented 83% of total revenues (2004: 80%). This excerpt taken from the SHPGY 8-K filed Apr 29, 2005. 2. Product sales For the three months to March 31, 2005, product sales increased 2% to $269.4 million (2004: $264.6 million) and represented 81% of total revenues (2004: 82%). This excerpt taken from the SHPGY 10-K filed Mar 15, 2005. (i) Product sales Revenue for the sales of products is recognized upon shipment to customers or at the time of delivery depending on the terms of sale. Provisions for rebates, product returns and discounts to customers are provided for as reductions to revenue in the same period as the related sales are recorded. The Company monitors and tracks the amount of rebates, product returns and discounts to customers based on historical experience to estimate the amount of reduction to revenue. This excerpt taken from the SHPGY 8-K filed Mar 2, 2005. 2. Product sales For the year to December 31, 2004 product sales increased by 11% to $1,112.5 million (2003: $1,004.3 million) and represented 82% of total revenues (2003: 83%). | EXCERPTS ON THIS PAGE: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
